{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:06:58Z","timestamp":1777579618531,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA194600"],"award-info":[{"award-number":["R01CA194600"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonsurgical management of ductal carcinoma in situ is controversial and little is known about the long-term consequences of this approach. In this study, we aimed to determine the risk of (a) upstaging to invasive carcinoma at excision and (b) ipsilateral breast cancer events in patients who might have been eligible for nonsurgical management of DCIS trials. Data from women aged 20 years or older with a biopsy diagnosis of DCIS between January 1, 2010 to December 31, 2014 were collated. The women underwent biopsy and surgical resection (lumpectomy or mastectomy) and were treated with radiation or endocrine therapy as per treating physicians\u2019 choice. The development of ipsilateral breast cancer events (IBEs) was analyzed in patients with at least 5 years of follow-up after standard of care therapy for DCIS. Subset-analysis was undertaken to identify the incidence of IBEs in patients eligible for nonsurgical management trials. The study population consisted of 378 patients with matched cases of biopsy and surgical excision. The overall upstaging rate to IBC was 14.3 and 12.9% for COMET, 8.8% for LORIS, and 10.7% for LORD trial \u201celigible\u201d patients. At 5 years of follow-up, ~11.5% of overall and trial eligible patients developed IBEs of which approximately half were invasive IBEs. In conclusion, women with DCIS who would have been eligible for nonsurgical management trials have a significantly high risk of developing ipsilateral breast events within 5 years of diagnosis. Better selection criteria are needed to identify DCIS patients who are at very low risk for the development of IBC.<\/jats:p>","DOI":"10.1038\/s41523-022-00420-2","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T10:04:48Z","timestamp":1651140288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Is conservative management of ductal carcinoma in situ risky?"],"prefix":"10.1038","volume":"8","author":[{"given":"Lan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9927-4893","authenticated-orcid":false,"given":"Yesim","family":"G\u00f6kmen-Polar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-9980","authenticated-orcid":false,"given":"Sunil S.","family":"Badve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"420_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jamcollsurg.2019.01.018","volume":"228","author":"TO Oseni","year":"2019","unstructured":"Oseni, T. O. et al. Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J. Am. Coll. Surg. 228, 932\u2013939 (2019).","journal-title":"J. Am. Coll. Surg."},{"key":"420_CR2","unstructured":"Pinder, S. E. et al. In WHO classificaiton of tumors series, 5th ed.; 2 Ch. Ductal Carcinoma in Situ, 76-81 (2019)."},{"key":"420_CR3","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","volume":"367","author":"A Bleyer","year":"2012","unstructured":"Bleyer, A. & Welch, H. G. Effect of three decades of screening mammography on breast-cancer incidence. N. Engl. J. Med. 367, 1998\u20132005 (2012).","journal-title":"N. Engl. J. Med."},{"key":"420_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.pathol.2019.07.005","volume":"51","author":"SS Badve","year":"2019","unstructured":"Badve, S. S. & Gokmen-Polar, Y. Ductal carcinoma in situ of breast: update 2019. Pathology 51, 563\u2013569 (2019).","journal-title":"Pathology"},{"key":"420_CR5","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm, L. J. et al. Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. Ann. Surg. Oncol. 24, 3534\u20133540 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"420_CR6","first-page":"1183","volume":"34","author":"JC Hogue","year":"2014","unstructured":"Hogue, J. C. et al. Characteristics associated with upgrading to invasiveness after surgery of a DCIS diagnosed using percutaneous biopsy. Anticancer Res. 34, 1183\u20131191 (2014).","journal-title":"Anticancer Res."},{"key":"420_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.breast.2012.06.012","volume":"21","author":"J Kim","year":"2012","unstructured":"Kim, J. et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast 21, 641\u2013645 (2012).","journal-title":"Breast"},{"key":"420_CR8","doi-asserted-by":"publisher","unstructured":"Lamb, L. R., Kim, G., Oseni, T. O. & Bahl, M. Noncalcified ductal carcinoma in situ (DCIS): rate and predictors of upgrade to invasive carcinoma. Acad. Radiol. https:\/\/doi.org\/10.1016\/j.acra.2020.02.011 (2020).","DOI":"10.1016\/j.acra.2020.02.011"},{"key":"420_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12282-018-0871-7","volume":"25","author":"Y Watanabe","year":"2018","unstructured":"Watanabe, Y. et al. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. Breast Cancer 25, 663\u2013670 (2018).","journal-title":"Breast Cancer"},{"key":"420_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.20892\/j.issn.2095-3941.2018.0159","volume":"16","author":"J Si","year":"2019","unstructured":"Si, J. et al. Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy. Cancer Biol. Med. 16, 312\u2013318 (2019).","journal-title":"Cancer Biol. Med."},{"key":"420_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-019-05362-1","volume":"178","author":"GS Mannu","year":"2019","unstructured":"Mannu, G. S. et al. Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study. Breast Cancer Res. Treat. 178, 409\u2013418 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"420_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.amjsurg.2018.12.069","volume":"217","author":"WW Sheaffer","year":"2019","unstructured":"Sheaffer, W. W. et al. Predictive factors of upstaging DCIS to invasive carcinoma in BCT vs mastectomy. Am. J. Surg. 217, 1025\u20131029 (2019).","journal-title":"Am. J. Surg."},{"key":"420_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jamcollsurg.2004.11.012","volume":"200","author":"TW Yen","year":"2005","unstructured":"Yen, T. W. et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J. Am. Coll. Surg. 200, 516\u2013526 (2005).","journal-title":"J. Am. Coll. Surg."},{"key":"420_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1015-9584(10)60013-9","volume":"33","author":"MY Chan","year":"2010","unstructured":"Chan, M. Y. & Lim, S. Predictors of invasive breast cancer in ductal carcinoma in situ initially diagnosed by core biopsy. Asian J. Surg. 33, 76\u201382 (2010).","journal-title":"Asian J. Surg."},{"key":"420_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prp.2012.02.003","volume":"208","author":"X Catteau","year":"2012","unstructured":"Catteau, X., Simon, P. & Noel, J. C. Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. Pathol. Res. Pr. 208, 217\u2013220 (2012).","journal-title":"Pathol. Res. Pr."},{"key":"420_CR16","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","volume":"33","author":"LJ Solin","year":"2015","unstructured":"Solin, L. J. et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J. Clin. Oncol. 33, 3938\u20133944 (2015).","journal-title":"J. Clin. Oncol."},{"key":"420_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/sj.bjc.6605718","volume":"103","author":"SE Pinder","year":"2010","unstructured":"Pinder, S. E. et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR\/ANZ DCIS trial. Br. J. Cancer 103, 94\u2013100 (2010).","journal-title":"Br. J. Cancer"},{"key":"420_CR18","doi-asserted-by":"publisher","unstructured":"Morrow, M. & Winer, E. P. De-escalating breast cancer surgery-Where is the tipping point? JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4849 (2019).","DOI":"10.1001\/jamaoncol.2019.4849"},{"key":"420_CR19","doi-asserted-by":"publisher","unstructured":"Hwang, E. S., Thompson, A. M. & Wesseling, J. De-escalating breast cancer surgery for low-risk ductal carcinoma in situ. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0816 (2020).","DOI":"10.1001\/jamaoncol.2020.0816"},{"key":"420_CR20","unstructured":"Comparison of operative to moitoring and endocrine therapy (COMET) trial for low risk DCIS (COMET). http:\/\/clinicaltrials.gov\/ct2\/show.NCT02926911"},{"key":"420_CR21","unstructured":"Surgery versus active monitoring for LOw RISk ductal carcinoma in situ. http:\/\/isrctn.com\/ISRCTN27544579."},{"key":"420_CR22","unstructured":"Management of Low-risk DCIS (LORD). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02492607."},{"key":"420_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1524-4741.2011.01069.x","volume":"17","author":"JS Han","year":"2011","unstructured":"Han, J. S., Molberg, K. H. & Sarode, V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J. 17, 223\u2013229 (2011).","journal-title":"Breast J."},{"key":"420_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.breast.2012.06.009","volume":"21","author":"C Trentin","year":"2012","unstructured":"Trentin, C. et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast 21, 635\u2013640 (2012).","journal-title":"Breast"},{"key":"420_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/bjs.11377","volume":"107","author":"F Munck","year":"2020","unstructured":"Munck, F. et al. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. Br. J. Surg. 107, 96\u2013102 (2020).","journal-title":"Br. J. Surg."},{"key":"420_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ejso.2019.01.015","volume":"45","author":"LC Marques","year":"2019","unstructured":"Marques, L. C. et al. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! Eur. J. Surg. Oncol. 45, 1152\u20131155 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"420_CR27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.acra.2019.12.009","volume":"27","author":"V Selvakumaran","year":"2020","unstructured":"Selvakumaran, V. et al. Predicting upstaging of DCIS to invasive disease: radiologists\u2019s predictive performance. Acad. Radio. 27, 1580\u20131585 (2020).","journal-title":"Acad. Radio."},{"key":"420_CR28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ejso.2019.01.015","volume":"45","author":"Marques,","year":"2019","unstructured":"Marques, et al. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! Eur. J. Surg. Oncol. 45, 1152\u20131155 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"420_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.11102368","volume":"260","author":"ME Brennan","year":"2011","unstructured":"Brennan, M. E. et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260, 119\u2013128 (2011).","journal-title":"Radiology"},{"key":"420_CR30","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41379-019-0262-4","volume":"32","author":"BT Harrison","year":"2019","unstructured":"Harrison, B. T., Hwang, E. S., Partridge, A. H., Thompson, A. M. & Schnitt, S. J. Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Mod. Pathol. 32, 1257\u20131262 (2019).","journal-title":"Mod. Pathol."},{"key":"420_CR31","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1245\/s10434-016-5595-3","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie, M., Olcese, C., Patil, S. & Van Zee, K. J. Women with low-risk DCIS eligible for the LORIS trial after complete surgical excision: how low is their risk after standard therapy? Ann. Surg. Oncol. 23, 4253\u20134261 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"420_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.5858\/arpa.2017-0268-OA","volume":"142","author":"MB Podoll","year":"2018","unstructured":"Podoll, M. B. et al. Feasibility of the less is more approach in treating low-risk ductal carcinoma in situ diagnosed on core needle biopsy: ten-year review of ductal carcinoma in situ upgraded to invasion at surgery. Arch. Pathol. Lab Med. 142, 1120\u20131126 (2018).","journal-title":"Arch. Pathol. Lab Med."},{"key":"420_CR33","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-18-0201","volume":"24","author":"LL Visser","year":"2018","unstructured":"Visser, L. L. et al. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ-A nested case-control study. Clin. Cancer Res. 24, 3593\u20133601 (2018).","journal-title":"Clin. Cancer Res."},{"key":"420_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","volume":"319","author":"MJ van de Vijver","year":"1988","unstructured":"van de Vijver, M. J. et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 319, 1239\u20131245 (1988).","journal-title":"N. Engl. J. Med."},{"key":"420_CR35","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO;2-V","volume":"75","author":"CB Leal","year":"1995","unstructured":"Leal, C. B., Schmitt, F. C., Bento, M. J., Maia, N. C. & Lopes, C. S. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75, 2123\u20132131 (1995).","journal-title":"Cancer"},{"key":"420_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"2010","author":"G Early Breast Cancer Trialists\u2019 Coll","year":"2010","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative, G. et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. Monogr. 2010, 162\u2013177 (2010).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"420_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1054\/bjoc.2000.1618","volume":"84","author":"N Bijker","year":"2001","unstructured":"Bijker, N. et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br. J. Cancer 84, 539\u2013544 (2001).","journal-title":"Br. J. Cancer"},{"key":"420_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32362","volume":"146","author":"MR Van Bockstal","year":"2020","unstructured":"Van Bockstal, M. R., Agahozo, M. C., Koppert, L. B. & van Deurzen, C. H. M. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int. J. Cancer 146, 1189\u20131197 (2020).","journal-title":"Int. J. Cancer"},{"key":"420_CR39","doi-asserted-by":"publisher","first-page":"582134","DOI":"10.1155\/2013\/582134","volume":"2013","author":"W Zhou","year":"2013","unstructured":"Zhou, W. et al. A comparison of tumor biology in primary ductal carcinoma in situ recurring as invasive carcinoma versus a new in situ. Int. J. Breast Cancer 2013, 582134 (2013).","journal-title":"Int. J. Breast Cancer"},{"key":"420_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejca.2013.10.020","volume":"50","author":"E Karlsson","year":"2014","unstructured":"Karlsson, E. et al. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Eur. J. Cancer 50, 517\u2013524 (2014).","journal-title":"Eur. J. Cancer"},{"key":"420_CR41","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","volume":"23","author":"L Lowenfeld","year":"2017","unstructured":"Lowenfeld, L. et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial. Clin. Cancer Res. 23, 2961\u20132971 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00420-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00420-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00420-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:26:26Z","timestamp":1669299986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00420-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1038\/s41523-022-00420-2","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}